Abstract
Steroids are the best known anti-inflammatory drugs and have been in use for more than 50 years. Their chronic use however was limited by safety concerns. Non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors although devoid of steroid side effects often possess gastrointestinal side effects. In addition recent data suggest that chronic use of some Cox inhibitors is associated with cardiovascular risk. Currently biologics represent the best option for many inflammatory diseases where TNFα is the main culprit. These include rheumatoid arthritis, ulcerative colitis, inflammatory bowel disease and psoriasis. A wealth of information is now available on the role of different cytokines and adhesion molecules in the origin and progression of inflammatory diseases. With the success of protein therapeutics such as Etanercept (Enbrel), which binds TNFα and inhibits its activity, research has been focused on developing small peptides that can interfere with cytokines or specific cell surface molecules and inhibit the inflammatory reactions. Here we review these peptides that are in discovery and development phases and their potential in the treatment of inflammatory diseases.
Keywords: NSAIDs, Inflammation, Reverse D-4F, AVP-26452, Complement C5a Antagonist, AI peptide
Current Pharmaceutical Biotechnology
Title: Emerging Peptide Therapeutics for Inflammatory Diseases
Volume: 7 Issue: 4
Author(s): Maya Vally, Sujatha Seenu and Sivaram Pillarisetti
Affiliation:
Keywords: NSAIDs, Inflammation, Reverse D-4F, AVP-26452, Complement C5a Antagonist, AI peptide
Abstract: Steroids are the best known anti-inflammatory drugs and have been in use for more than 50 years. Their chronic use however was limited by safety concerns. Non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors although devoid of steroid side effects often possess gastrointestinal side effects. In addition recent data suggest that chronic use of some Cox inhibitors is associated with cardiovascular risk. Currently biologics represent the best option for many inflammatory diseases where TNFα is the main culprit. These include rheumatoid arthritis, ulcerative colitis, inflammatory bowel disease and psoriasis. A wealth of information is now available on the role of different cytokines and adhesion molecules in the origin and progression of inflammatory diseases. With the success of protein therapeutics such as Etanercept (Enbrel), which binds TNFα and inhibits its activity, research has been focused on developing small peptides that can interfere with cytokines or specific cell surface molecules and inhibit the inflammatory reactions. Here we review these peptides that are in discovery and development phases and their potential in the treatment of inflammatory diseases.
Export Options
About this article
Cite this article as:
Vally Maya, Seenu Sujatha and Pillarisetti Sivaram, Emerging Peptide Therapeutics for Inflammatory Diseases, Current Pharmaceutical Biotechnology 2006; 7 (4) . https://dx.doi.org/10.2174/138920106777950816
DOI https://dx.doi.org/10.2174/138920106777950816 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Biology of p38 Kinase: A Central Role in Inflammation
Current Topics in Medicinal Chemistry Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry ‘Osteoimmunology' Offers New Perspectives for the Treatment of Pathological Bone Loss
Current Pharmaceutical Design B-Cell Based Gene Therapy for Autoimmune Diseases
Infectious Disorders - Drug Targets The Role of Quercetin, Flavonols and Flavones in Modulating Inflammatory Cell Function
Inflammation & Allergy - Drug Targets (Discontinued) Gene Therapy and Biologic Therapy with Interleukin?4
Current Gene Therapy The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design TNFα Modulation of Visceral and Spinal Sensory Processing
Current Pharmaceutical Design Effects of Antioxidant Polyphenols on TNF-Alpha-Related Diseases
Current Topics in Medicinal Chemistry Influence of the OATP Polymorphism on the Population Pharmacokinetics of Methotrexate in Chinese Patients
Current Drug Metabolism Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!
CNS & Neurological Disorders - Drug Targets Novel Approaches to Study the Involvement of α7-nAChR in Human Diseases
Current Drug Targets Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Chemistry and Biology of Anti-Inflammatory Marine Natural Products:Molecules Interfering with Cyclooxygenase, NF-kB and Other Unidentified Targets
Current Medicinal Chemistry Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach
Current Medicinal Chemistry Novel Strategies for the Treatment of Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Cysteine-Rich Mini-Proteins in Human Biology
Current Topics in Medicinal Chemistry NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters